ArticleGastroenterology2023
TET1 and TDG Suppress Inflammatory Response in Intestinal Tumorigenesis: Implications for Colorectal Tumors With the CpG Island Methylator Phenotype.
Open access · bronzeAbstract read
In one paragraph
Article in Gastroenterology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
4.0field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 26 citations in OpenAlex.
- DNA methylation signatures of sporadic colorectal cancer with microsatellite instability.Epigenetics · 2026Article
- TET Enzymes as Epigenetic Integrators in Intestinal Immunity, Inflammation, and Disease.Journal of personalized medicine · 2026Review
- Prognostic model construction and drug prediction in colorectal cancer using mitochondrial programmed cell death-related genes.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Integrated Multi-Omics Profiling Identifies an Immunotherapy Vulnerable and Prognostic Associated Subtype in Cholangiocarcinoma.Liver cancer · 2026Article
- Article
- Iron homeostasis and cell clonality drive cancer-associated intestinal DNA methylation drift in aging.Nature aging · 2025Article
- DNA, RNA, and histone methylation regulation enzymes and their crosstalk in colorectal carcinogenesis and progression: a review of molecular mechanisms, clinical implications, and future perspectives.Cellular & molecular biology letters · 2025Review
- TET1: The epigenetic architect of clinical disease progression.Genes & diseases · 2025Review
- Ten-Eleven Translocation Family Proteins: Structure, Biological Functions, Diseases, and Targeted Therapy.MedComm · 2025Review
- Screening of pivotal oncogenes modulated by DNA methylation in hepatocellular carcinoma and identification of atractylenolide I as an anti-cancer drug.Human cell · 2025Article
- Simulation-guided pan-cancer analysis identifies a novel regulator of CpG island hypermethylation heterogeneity.Briefings in bioinformatics · 2025Article
- The Role of DNA Methylation in Gastrointestinal Disease: An Expanded Review of Malignant and Nonmalignant Gastrointestinal Diseases.Gastroenterology · 2025Review
- Whole-Genome Resequencing to Identify Selection Signatures Associated with High Fertility in Lüliang Black Goat.Animals : an open access journal from MDPI · 2024Article
- PPM1G Inhibits Epithelial-Mesenchymal Transition in Cholangiocarcinoma by Catalyzing TET1 Dephosphorylation for Destabilization to Impair Its Targeted Demethylation of the CLDN3 Promoter.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Vitamin C enhances co-localization of novel TET1 nuclear bodies with both Cajal and PML bodies in colorectal cancer cells.Epigenetics · 2024Article
- The implication of TET1, miR-200, and miR-494 expression with tumor formation in colorectal cancer: through targeting Wnt signaling.Molecular biology reports · 2024Article
- DNA Methylation Classes of Stage II and III Primary Melanomas and Their Clinical and Prognostic Significance.JCO precision oncology · 2024Article
- Immune microenvironmental heterogeneity according to tumor DNA methylation phenotypes in microsatellite instability-high colorectal cancers.Cancer immunology, immunotherapy : CII · 2024Article
- Epigenetic modulators provide a path to understanding disease and therapeutic opportunity.Genes & development · 2024Review
- The Killer's Web: Interconnection between Inflammation, Epigenetics and Nutrition in Cancer.International journal of molecular sciences · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
41 authors at 7 institutions in 3 countries.
Rossella TricaricoCancer Epigenetics Institute, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Nuclear Dynamics and Cancer Program, Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Jozef MadzoCoriell Institute for Medical Research, Camden, New Jersey.
Gabrielle ScherCancer Epigenetics Institute, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Nuclear Dynamics and Cancer Program, Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Maya CohenCancer Epigenetics Institute, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Nuclear Dynamics and Cancer Program, Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Jaroslav JelinekCoriell Institute for Medical Research, Camden, New Jersey.
Shinji MaegawaUniversity of Texas M.D. Anderson Cancer Center, Houston, Texas.
Rajeswari NagarathinamDepartment of Pathology, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Carly ScherCancer Epigenetics Institute, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Nuclear Dynamics and Cancer Program, Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Wen-Chi ChangCancer Prevention and Control Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Emmanuelle NicolasCancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Michael SlifkerDepartment of Biostatistics, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Yan ZhouDepartment of Biostatistics, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Karthik DevarajanDepartment of Biostatistics, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Kathy Q CaiExperimental Histopathology, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Tim KwokCell Culture Facility, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Pamela NakajimaCell Culture Facility, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Jinfei XuCancer Epigenetics Institute, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Nuclear Dynamics and Cancer Program, Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Pietro MancusoCancer Epigenetics Institute, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Nuclear Dynamics and Cancer Program, Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Valentina DonedduCancer Epigenetics Institute, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Nuclear Dynamics and Cancer Program, Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Luigi BagellaDepartment of Biomedical Sciences, University of Sassari, Sassari, Italy; Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, Pennsylvania.
Riley WilliamsCancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Siddharth BalachandranCancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Nicholas MaskalenkoCancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Kerry CampbellCancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Xueying MaNuclear Dynamics and Cancer Program, Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Israel CañadasCancer Epigenetics Institute, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Nuclear Dynamics and Cancer Program, Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Julen Viana-ErrastiHereditary Cancer Program Catalan Institute of Oncology, Oncobell Program, Investigación Biomédica de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain.
Victor MorenoOncology Data Analytics Program, Catalan Institute of Oncology, Oncobell Program, Investigación Biomédica de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain; Consorcio de Investigación Biomédica en Red de Epidemiología y Salud Pública, Madrid, Spain; Department of Clinical Sciences, Faculty of Medicine, University of Barcelona, Barcelona, Spain.
Laura ValleHereditary Cancer Program Catalan Institute of Oncology, Oncobell Program, Investigación Biomédica de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain; Centro de Investigación Biomédica en Red de Cáncer, Madrid, Spain.
Sergei GrivennikovCancer Prevention and Control Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Department of Medicine and Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, California.
Iuliia PeshkovaCancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Department of Medicine and Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, California.
Natalia KurilenkoCancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Department of Medicine and Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, California.
Aleksandra MazitovaCancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Department of Medicine and Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, California.
Ekaterina KoltsovaCancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Department of Medicine and Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, California.
Hayan LeeCancer Epigenetics Institute, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Nuclear Dynamics and Cancer Program, Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Martin WalshCancer Epigenetics Institute, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Nuclear Dynamics and Cancer Program, Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Reuben DuttweilerCancer Epigenetics Institute, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Nuclear Dynamics and Cancer Program, Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Johnathan R WhetstineCancer Epigenetics Institute, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Nuclear Dynamics and Cancer Program, Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Timothy J YenCancer Epigenetics Institute, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Nuclear Dynamics and Cancer Program, Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Jean-Pierre IssaCoriell Institute for Medical Research, Camden, New Jersey.
Alfonso BellacosaCancer Epigenetics Institute, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Nuclear Dynamics and Cancer Program, Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, Pennsylvania. Electronic address: Alfonso.Bellacosa@fccc.edu.
Fox Chase Cancer Center · USCedars-Sinai Medical Center · USCoriell Institute For Medical Research · USInstitut Català d'Oncologia · ESInstitut d'Investigació Biomédica de Bellvitge · ESThe University of Texas MD Anderson Cancer Center · USUniversity of Sassari · IT
Funding
WORD PROCESSING CENTER--COREP30CA006927 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI Dietmar J Kappes · 1985 to 2026
$138.8MThe MED1 Protein in DNA Damage Response and RepairR01CA078412 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI BELLACOSA, ALFONSO · 2004 to 2014
$3.7MMechanisms of cytokine driven tumor elicited inflammation in colorectal cancerR01CA218133 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI GRIVENNIKOV, SERGEI I · 2018 to 2022
$2.4MDeciphering Networks Controlling DNA AmplificationR35GM144131 · NIGMS · RESEARCH INST OF FOX CHASE CAN CTR · PI Johnathan R. Whetstine · 2022 to 2026
$2.3MNEW HUMAN DNA REPAIR ENDONUCLEASER29CA078412 · NCI · FOX CHASE CANCER CENTER · PI BELLACOSA, ALFONSO · 1998 to 2002
$619kTDG as a novel target to enhance gemcitabine killing of pancreatic cancer cellsR21CA191956 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI BELLACOSA, ALFONSO, YEN, TIMOTHY · 2015 to 2016
$427kIdentification of first-in-class epigenetic inhibitors that target Thymine DNA Glycosylase (TDG) for future precision therapy of metastatic melanomaR03CA256762 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI BELLACOSA, ALFONSO, YEN, TIMOTHY · 2021 to 2022
$187kNCI NIH HHS P30 CA006927NCI NIH HHS R01 CA078412NCI NIH HHS R01 CA218133NCI NIH HHS R03 CA256762NCI NIH HHS R21 CA191956NCI NIH HHS R29 CA078412NIGMS NIH HHS R35 GM144131
Abstract
BACKGROUND &
aimsAberrant DNA methylation is frequent in colorectal cancer (CRC), but underlying mechanisms and pathologic consequences are poorly understood.
methodsWe disrupted active DNA demethylation genes Tet1 and/or Tdg from Apc
resultsThere were increased numbers of small intestinal adenomas in Apc
conclusionsOur findings reveal a novel epigenetic regulation, linked to the type of genomic instability, by which TET1/TDG-mediated DNA demethylation decreases methylation levels and inflammatory/interferon/immune responses. CIMP in CRC is triggered by an imbalance of methylating activities over demethylating activities. These mice represent a model of CIMP CRC.
Indexed as
AdenocarcinomaAdenomaColonic NeoplasmsColorectal NeoplasmsAnimalsCarcinogenesisCell Transformation, NeoplasticCpG IslandsDNA-Binding ProteinsDNA MethylationEpigenesis, GeneticHumansMiceMixed Function OxygenasesPhenotypeProto-Oncogene ProteinsDNA-Binding ProteinsMixed Function OxygenasesProto-Oncogene ProteinsTdg protein, mouseTET1 protein, humanTET1 protein, mouseThymine DNA GlycosylaseCpG Island Methylator PhenotypeDNA DemethylationDNA MethylationInflammatory ResponseInterferon Response
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.